Importance: Patients with germline mutations in BAP1 may develop several flesh-colored melanocytic BAP1-mutated atypical intradermal tumors (MBAITs). These tumors generally develop earlier than other BAP1-associated tumors, highlighting an important role for dermatologists in identifying and screening patients with a history suggestive of a germline mutation. Objective: To describe 8 new families with germline mutations in BAP1 and provide a comprehensive review of reported cases. Design, Settings and Participants: Patients were identified in an outpatient dermatology clinical setting over a 6-month period (10 mutation carriers from 8 families) and through a literature review using PubMed (205 patients). Exposures: Mutations were identified through next-generation sequencing of saliva or blood samples, and RNA was extracted from fibroblasts cultured from a patient with an intronic variant to determine the impact of the mutation on the coding sequence. Main Outcomes and Measures: All 215 patients were assessed for personal and/or family history and genotype. These findings were compiled and assessed for any association between genotype and phenotype. Results: Overall, this study included 215 patients (108 women, 91 men, and 16 gender unspecified; median [range] age, 46.5 [10.0-79.0] years). Nine of the 10 patients who were identified in the outpatient dermatology setting were found to have MBAITs on clinical examination. Forty of 53 patients (75%) identified in the literature review who underwent total-body skin examinations (TBSE) were found to have MBAITs, suggesting a high penetrance in patients who have undergone TBSE. The most prevalent malignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]). A total of 71 unique mutations in BAP1 have been reported. Conclusions and Relevance: Our results indicate that germline mutations in both coding and noncoding regions throughout the BAP1 gene can impair protein function, leading to an increased risk for several associated malignancies. Four of the 8 probands we present had no history of BAP1-associated malignancies and were assessed for germline mutations when found to have MBAITs on dermatologic examination. Dermatologists can identify patients with a high likelihood of the BAP1 cancer syndrome through personal and family history and TBSE for the presence of possible MBAITs.
Importance: Patients with germline mutations in BAP1 may develop several flesh-colored melanocytic BAP1-mutated atypical intradermal tumors (MBAITs). These tumors generally develop earlier than other BAP1-associated tumors, highlighting an important role for dermatologists in identifying and screening patients with a history suggestive of a germline mutation. Objective: To describe 8 new families with germline mutations in BAP1 and provide a comprehensive review of reported cases. Design, Settings and Participants: Patients were identified in an outpatient dermatology clinical setting over a 6-month period (10 mutation carriers from 8 families) and through a literature review using PubMed (205 patients). Exposures: Mutations were identified through next-generation sequencing of saliva or blood samples, and RNA was extracted from fibroblasts cultured from a patient with an intronic variant to determine the impact of the mutation on the coding sequence. Main Outcomes and Measures: All 215 patients were assessed for personal and/or family history and genotype. These findings were compiled and assessed for any association between genotype and phenotype. Results: Overall, this study included 215 patients (108 women, 91 men, and 16 gender unspecified; median [range] age, 46.5 [10.0-79.0] years). Nine of the 10 patients who were identified in the outpatient dermatology setting were found to have MBAITs on clinical examination. Forty of 53 patients (75%) identified in the literature review who underwent total-body skin examinations (TBSE) were found to have MBAITs, suggesting a high penetrance in patients who have undergone TBSE. The most prevalent malignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]). A total of 71 unique mutations in BAP1 have been reported. Conclusions and Relevance: Our results indicate that germline mutations in both coding and noncoding regions throughout the BAP1 gene can impair protein function, leading to an increased risk for several associated malignancies. Four of the 8 probands we present had no history of BAP1-associated malignancies and were assessed for germline mutations when found to have MBAITs on dermatologic examination. Dermatologists can identify patients with a high likelihood of the BAP1cancer syndrome through personal and family history and TBSE for the presence of possible MBAITs.
Authors: Mrinali P Gupta; Anne Marie Lane; Margaret M DeAngelis; Katie Mayne; Margaux Crabtree; Evangelos S Gragoudas; Ivana K Kim Journal: JAMA Ophthalmol Date: 2015-08 Impact factor: 7.389
Authors: J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock Journal: Science Date: 2010-11-04 Impact factor: 47.728
Authors: Colleen M Cebulla; Elaine M Binkley; Robert Pilarski; James B Massengill; Karan Rai; David A Liebner; Meghan J Marino; Arun D Singh; Mohamed H Abdel-Rahman Journal: Ophthalmic Genet Date: 2015-02-17 Impact factor: 1.803
Authors: Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei Journal: J Toxicol Environ Health B Crit Rev Date: 2011 Impact factor: 6.393
Authors: Megan N Farley; Laura S Schmidt; W Marston Linehan; James Brugarolas; Jessica L Mester; Samuel Pena-Llopis; Andrea Pavia-Jimenez; Alana Christie; Cathy D Vocke; Christopher J Ricketts; James Peterson; Lindsay Middelton; Lisa Kinch; Nick Grishin; Maria J Merino; Adam R Metwalli; Chao Xing; Xian-Jin Xie; Patricia L M Dahia; Charis Eng Journal: Mol Cancer Res Date: 2013-05-24 Impact factor: 5.852
Authors: Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: K A W Wadt; L G Aoude; P Johansson; A Solinas; A Pritchard; O Crainic; M T Andersen; J F Kiilgaard; S Heegaard; L Sunde; B Federspiel; J Madore; J F Thompson; S W McCarthy; A Goodwin; H Tsao; G Jönsson; K Busam; R Gupta; J M Trent; A-M Gerdes; K M Brown; R A Scolyer; N K Hayward Journal: Clin Genet Date: 2014-11-06 Impact factor: 4.438
Authors: Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Michele Carbone; Sarah T Arron; Bruce Beutler; Angela Bononi; Webster Cavenee; James E Cleaver; Carlo M Croce; Alan D'Andrea; William D Foulkes; Giovanni Gaudino; Joanna L Groden; Elizabeth P Henske; Ian D Hickson; Paul M Hwang; Richard D Kolodner; Tak W Mak; David Malkin; Raymond J Monnat; Flavia Novelli; Harvey I Pass; John H Petrini; Laura S Schmidt; Haining Yang Journal: Nat Rev Cancer Date: 2020-05-29 Impact factor: 60.716
Authors: Michael R Sargen; Donato Calista; David E Elder; Daniela Massi; Emily Y Chu; Míriam Potrony; Ruth M Pfeiffer; Cristina Carrera; Paula Aguilera; Llucia Alos; Susana Puig; Rosalie Elenitsas; Xiaohong R Yang; Margaret A Tucker; Maria Teresa Landi; Alisa M Goldstein Journal: J Am Acad Dermatol Date: 2020-04-10 Impact factor: 11.527
Authors: Oriol Yélamos; Cristián Navarrete-Dechent; Michael A Marchetti; Tova Rogers; Zoe Apalla; Philippe Bahadoran; Nuria Blázquez-Sánchez; Klaus Busam; Cristina Carrera; Stephen W Dusza; Arnaud de la Fouchardière; Gerardo Ferrara; Pedram Gerami; Harald Kittler; Aimilios Lallas; Josep Malvehy; José F Millán-Cayetano; Kelly C Nelson; Victor Li Quan; Susana Puig; Howard Stevens; Luc Thomas; Ashfaq A Marghoob Journal: J Am Acad Dermatol Date: 2018-09-20 Impact factor: 11.527